Investigational agent significantly improved PFS in patients with HER-2–positive advanced breast cancer

  • June 29, 2012

Adam M. Brufksy, MD, PhD, discusses results from the phase 3 EMILIA trial. The findings, presented at the ASCO plenary session, could present a new treatment option for women with HER-2–positive tumors without the usual adverse effects of chemotherapy.

Comments

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]